Literature DB >> 31408190

Genetic alterations in primary melanoma in Taiwan.

Y-S Sheen1, K-T Tan2, K-P Tse2, Y-H Liao1, M-H Lin3,4, J-S Chen1, J-Y Liau5, Y-J Tseng6, C-H Lee6,7, C-H Hong8,9, J-B Liao10, H-T Chang11,12, C-Y Chu1.   

Abstract

BACKGROUND: Acral melanoma (AM) is the most common histopathological subtype of malignant melanoma in Asians. However, differences in the mutational profiles underlying AM and nonacral cutaneous melanoma (NAM) in Asians are not well understood.
OBJECTIVES: To augment the understanding of the prevalence, patterns and associations of various mutations between different subtypes of melanoma.
METHODS: We performed comprehensive genomic profiling of 409 cancer-associated genes, using next-generation sequencing, in 66 primary melanomas comprised of 45 AMs and 21 NAMs.
RESULTS: Most of the AMs (n = 27/45; 60%), but only five of 21 (24%) NAMs, were triple wild-type (triple-WT) tumours. Compared with AMs, NAMs exhibited a significantly higher frequency of BRAF mutations. The frequencies of NRAS/KRAS mutations, cell-cycle aberrations, copy number gains in BIRC2, BIRC3 and BIRC5, and gains of receptor tyrosine kinase genes were significantly higher in AMs. Ulceration was found at significantly higher rates in the AMs and NAMs with cell-cycle aberrations and gains of receptor tyrosine kinase genes. Notably, cell-cycle aberrations and copy number gains in BIRC2, BIRC3 and BIRC5 were significantly associated with poor melanoma-specific survival in the 66 patients with melanoma and especially in the 45 patients with AM. Multivariate analysis showed that lymph node metastasis and cell-cycle aberrations were independent prognostic factors of melanoma-specific survival.
CONCLUSIONS: This study strengthens our understanding of the patterns and clinical associations of oncogenic mutations in AMs and NAMs in Asians. What's already known about this topic? Mutation frequencies of driver genes vary between melanoma subtypes. Acral melanoma is the most common subtype of melanoma in Asians. KIT mutations and copy number variations occur more frequently in the acral subtype of melanoma than in the nonacral subtype What does this study add? NRAS/KRAS mutations, cell-cycle aberrations, copy number gains in BIRC2, BIRC3 and BIRC5, and amplifications of receptor tyrosine kinase genes were significantly enriched in acral melanoma and could be potential targets for treatment. Melanomas with cell-cycle aberrations and gains in receptor tyrosine kinase genes were significantly more likely to contain ulceration. What is the translational message? Cell-cycle aberrations and copy number gains in BIRC2, BIRC3 and BIRC5 were significantly associated with poor melanoma-specific survival. These observations should be explored further for future drug development.
© 2019 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31408190     DOI: 10.1111/bjd.18425

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

Review 1.  Acral Melanocytic Neoplasms: A Comprehensive Review of Acral Nevus and Acral Melanoma in Asian Perspective.

Authors:  Sanghyun Park; Sook-Jung Yun
Journal:  Dermatopathology (Basel)       Date:  2022-08-19

Review 2.  More than just acral melanoma: the controversies of defining the disease.

Authors:  Sara S Bernardes; Ingrid Ferreira; David E Elder; Aretha B Nobre; Héctor Martínez-Said; David J Adams; Carla Daniela Robles-Espinoza; Patricia A Possik
Journal:  J Pathol Clin Res       Date:  2021-07-02

3.  Establishment of cultured primary acral melanoma cells and animal models for Chinese patients.

Authors:  Rui Hu; Shuang Zhao; Juan Su; Xiang Chen; Mingzhu Yin
Journal:  Pigment Cell Melanoma Res       Date:  2021-06-28       Impact factor: 4.159

4.  Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition.

Authors:  Jian-Ching Wu; Han-En Tsai; Yi-Hsiang Hsiao; Ji-Syuan Wu; Chieh-Shan Wu; Ming-Hong Tai
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

5.  Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.

Authors:  Takamichi Ito; Yumiko Kaku-Ito; Maho Murata; Kazuhisa Furue; Che-Hung Shen; Yoshinao Oda; Masutaka Furue
Journal:  J Clin Med       Date:  2020-03-04       Impact factor: 4.241

6.  Characterizations of Gene Alterations in Melanoma Patients from Chinese Population.

Authors:  Yi Luo; Zhenzhen Zhang; Jianfan Liu; Linqing Li; Xuezheng Xu; Xinyu Yao; Zixun Dai; Xin Wang; Shuo Yang; Hongwei Wu; Jie Bu; Yuan Wu; Tianmin Xiang; Xianan Li
Journal:  Biomed Res Int       Date:  2020-01-30       Impact factor: 3.411

7.  Mutational profiling of melanomas in patients from the southeast coast of China.

Authors:  Ai-Wen Zheng; Dong-Dong Jia; Cheng-Cheng Zhou; Tao Li
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

8.  Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan.

Authors:  Tung-Lin Lee; Yi-Hua Liao; Jau-Yu Liau; Yi-Shuan Sheen
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

9.  m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation.

Authors:  Zhanghui Yue; Meng Cao; Anlan Hong; Qian Zhang; Guoqiang Zhang; Zhibin Jin; Liang Zhao; Qiang Wang; Fang Fang; Yan Wang; Jianfang Sun
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244

10.  Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.

Authors:  Anna Fäldt Beding; Peter Larsson; Khalil Helou; Zakaria Einbeigi; Toshima Z Parris
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.